Mia J Biondi1,2, Grishma Hirode1,2, Camelia Capraru1, Aaron Vanderhoff1, Joel Karkada1, Brett Wolfson-Stofko1, David Smookler1, Steven M Friedman3, Kathy Bates4, Tony Mazzulli5,6, Joshua V Juan7, Hemant Shah1, Bettina E Hansen1, Jordan J Feld8,1, Harry LA Janssen8,1. 1. Toronto Centre for Liver Disease/Viral Hepatitis Care Network (VIRCAN), University Health Network, Toronto, Ontario, Canada. 2. These first authors contributed equally to this work. 3. Department of Emergency Medicine, University Health Network, Toronto, Ontario, Canada. 4. Emergency Department, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada. 5. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. 6. Department of Microbiology, University Health Network/Sinai Health System, Toronto, Ontario, Canada. 7. Albany Medical Clinic, Toronto, Ontario, Canada. 8. These senior authors contributed equally to this work.
Abstract
Background: Widespread screening and treatment of hepatitis C virus (HCV) is required to decrease late-stage liver disease and liver cancer. Clinical practice guidelines and Canadian Task Force on Preventative Health Care recommendations differ on the value of one-time birth cohort (1945-75) HCV screening in Canada. To assess the utility of this approach, we conducted a real-world analysis of HCV antibody (Ab) prevalence among birth cohort individuals seen in different clinical contexts. Methods: Cross-sectional study of individuals born between 1945 and 1975 who completed HCV Ab testing at multiple participating centres in Ontario, Canada between January 2016 and December 2020. Differences in prevalence were compared by year of birth, gender, and setting. Results: Among 16,672 birth cohort individuals tested, HCV Ab prevalence was 3.2%. Prevalence was higher among younger individuals which increased from 0.9% among those born between 1945 and 1956 to 4.6% among those born between 1966 and 1975. Prevalence was higher among males (4.4%) compared with females (2.0%) and differed by test site. In primary care, the prevalence was 0.5%, whereas the prevalence was highest among those tested at drug treatment centres (28.7%) and through community outreach (14.0%). Conclusions: HCV Ab prevalence remains high in the 1945-1975 birth cohort. These data highlight the need to re-evaluate existing Canadian Preventative Task Force recommendations, to consider incorporating one-time birth cohort and/or other population-based approaches to HCV screening into the clinical workflow as a preventative health measure, and to increase training among community providers to screen for and treat HCV.
Background: Widespread screening and treatment of hepatitis C virus (HCV) is required to decrease late-stage liver disease and liver cancer. Clinical practice guidelines and Canadian Task Force on Preventative Health Care recommendations differ on the value of one-time birth cohort (1945-75) HCV screening in Canada. To assess the utility of this approach, we conducted a real-world analysis of HCV antibody (Ab) prevalence among birth cohort individuals seen in different clinical contexts. Methods: Cross-sectional study of individuals born between 1945 and 1975 who completed HCV Ab testing at multiple participating centres in Ontario, Canada between January 2016 and December 2020. Differences in prevalence were compared by year of birth, gender, and setting. Results: Among 16,672 birth cohort individuals tested, HCV Ab prevalence was 3.2%. Prevalence was higher among younger individuals which increased from 0.9% among those born between 1945 and 1956 to 4.6% among those born between 1966 and 1975. Prevalence was higher among males (4.4%) compared with females (2.0%) and differed by test site. In primary care, the prevalence was 0.5%, whereas the prevalence was highest among those tested at drug treatment centres (28.7%) and through community outreach (14.0%). Conclusions: HCV Ab prevalence remains high in the 1945-1975 birth cohort. These data highlight the need to re-evaluate existing Canadian Preventative Task Force recommendations, to consider incorporating one-time birth cohort and/or other population-based approaches to HCV screening into the clinical workflow as a preventative health measure, and to increase training among community providers to screen for and treat HCV.
Authors: Bryce D Smith; Rebecca L Morgan; Geoff A Beckett; Yngve Falck-Ytter; Deborah Holtzman; Chong-Gee Teo; Amy Jewett; Brittney Baack; David B Rein; Nita Patel; Miriam Alter; Anthony Yartel; John W Ward Journal: MMWR Recomm Rep Date: 2012-08-17
Authors: Alex D Federman; Natalie Kil; Joseph Kannry; Evie Andreopolous; Wilma Toribio; Joanne Lyons; Mark Singer; Anthony Yartel; Bryce D Smith; David B Rein; Katherine Krauskopf Journal: Med Care Date: 2017-06 Impact factor: 2.983
Authors: Robert P Myers; Mel Krajden; Marc Bilodeau; Kelly Kaita; Paul Marotta; Kevork Peltekian; Alnoor Ramji; Chris Estes; Homie Razavi; Morris Sherman Journal: Can J Gastroenterol Hepatol Date: 2014-05
Authors: James W Galbraith; Erik S Anderson; Yu-Hsiang Hsieh; Ricardo A Franco; John P Donnelly; Joel B Rodgers; Elissa M Schechter-Perkins; William W Thompson; Noele P Nelson; Richard E Rothman; Douglas A E White Journal: MMWR Morb Mortal Wkly Rep Date: 2020-05-15 Impact factor: 17.586
Authors: Monica L Kasting; Julie Rathwell; Kaitlyn M Gabhart; Jennifer Garcia; Richard G Roetzheim; Olveen Carrasquillo; Anna R Giuliano; Susan T Vadaparampil Journal: BMC Fam Pract Date: 2020-12-02 Impact factor: 2.497